The company's newest program is evaluating a series of internally developed dual amylin and calcitonin receptor agonists ... while driving significant reductions in plasma levels of very long-chain ...

The company's newest program is evaluating a series of internally developed dual amylin and calcitonin receptor ... while driving significant reductions in plasma levels of very long-chain fatty ...

The company's newest program is evaluating a series of internally developed dual amylin and calcitonin receptor ... while driving significant reductions in plasma levels of very long-chain fatty ...

Ton Annual Supply of VK2735 Active Pharmaceutical Ingredient. Secures Dedicated Fill/Finish Capacity for 100 Million Annua ...

Shares of Viking Therapeutics VKTX gained more than 11% on Wednesday after the company announced that it had signed a broad ...

Management plans to file an investigational new drug (IND) application with the FDA later this year to advance an internally developed dual amylin and ... reduced plasma levels of very long ...

Amneal’s network and facilities will help Metsera’s injectable and oral initiatives, which include GLP-1 and amylin receptor ... company specializing in plasma-derived therapies, diagnostics ...

Shares of Viking Therapeutics VKTX rose nearly 8% on Friday after several third-party reports suggested that it was being eyed for a potential takeover by pharma giant Pfizer PFE. These reports even ...

The Gubra drug a peptide engineered to be an analog for amylin, a hormone that helps regulate blood sugar and food intake. It is specifically designed to bind to and activate amylin and calcitonin ...

Zealand Pharma’s search for a partner for its amylin-based obesity therapy petrelintide remains ongoing, with no agreement announced in its 2024 earnings report. The company has yet to secure a ...

In addition, there will be a $350 million up-front payment as Abbvie takes over the reins of GUB-014295 (referred to as Gubamy), a long-acting analog of the satiety hormone amylin, currently in phase ...